The Career Development Program was designed to train and guide academic physician-scientists, clinicianinvestigators,and laboratory-based researchers who wish to dedicate their efforts to translational research inthe areas of diagnosis, prevention, and treatment of ovarian cancer. To meet this goal, the specific objectivesof the Career Development Program are to: Recruit and train young physician-scientists, clinician-investigators, and laboratory-based researchers tobecome leaders in translational research on ovarian cancer; Provide dedicated time to perform clinically relevant laboratory research and hypothesis-driven clinicaltrials; Provide support for translational research that will generate preliminary data and relevant publicationsfor a full SPORE project or for peer-reviewed funding outside the SPORE mechanism; Mentor effectively those chosen for career development; Offer educational experiences that address the unique needs of the awardees.The SPORE Career Development Awards involve 2 or more years of mentored research in ovarian cancer inwhich the investigators learn through their experience in conducting a research project with the advice of twomentors (one laboratory based and one clinical). Our mentors have been chosen for their expertise andinterest in ovarian cancer from the more than 1000 faculty at M. D. Anderson. The awardees can obtain moreformal training, including courses offered by The University of Texas-Houston Graduate School of BiomedicalSciences in molecular biology, genetics, biostatistics, epidemiology, physiology, and pharmacology. Theawardees can also participate in the M. D. Anderson K30 curriculum for clinical investigators and have theoption to earn an M.S. or Ph.D. in patient-based biological research. The M.S./Ph.D. program includes theseminar class Topics in Translational Research, which all our career development awardees will be required totake. All 10 awardees to date have published their ovarian cancer research, seven have obtained independentfunding, and two have become Co-Pis of full SPORE projects. The awardees have published a total of 63ovarian cancer papers and obtained 16 funded grants, including eight related directly to ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083639-09
Application #
7729385
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Project Start
2008-09-04
Project End
2010-08-31
Budget Start
2008-09-04
Budget End
2009-08-31
Support Year
9
Fiscal Year
2008
Total Cost
$123,789
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yuan, Jiao; Hu, Zhongyi; Mahal, Brandon A et al. (2018) Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34:549-560.e9
Liu, Xiaojun; Jiang, Yingjun; Nowak, Billie et al. (2018) Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Cancer Chemother Pharmacol 81:255-267
Haemmerle, Monika; Stone, Rebecca L; Menter, David G et al. (2018) The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 33:965-983
Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242
Umamaheswaran, Sujanitha; Dasari, Santosh K; Yang, Peiying et al. (2018) Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev 37:203-211
Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742
Huang, Yan; Hu, Wei; Huang, Jie et al. (2018) Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17:464-473
Yang, Hailing; Mao, Weiqun; Rodriguez-Aguayo, Cristian et al. (2018) Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24:5072-5084
Rhyasen, Garrett W; Yao, Yi; Zhang, Jingwen et al. (2018) BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS One 13:e0200826
Chen, Jian; Zaidi, Sobia; Rao, Shuyun et al. (2018) Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-? Pathway. Gastroenterology 154:195-210

Showing the most recent 10 out of 648 publications